Clinical trials: Peripheral T Cells Lymphoma (PTCL)
Non-Hodgkin Lymphoma, T-Cell Lymphoma
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL).
- Conditions
- Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
- Trial name
- SCORE-NHL (NCT07750886)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Natera, Inc.
Peripheral T-cell Lymphoma
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
This is a single-arm, single-center Phase II clinical trial for patients with relapsed or refractory Peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT04052659
- Testing
- Sintilimab, Chidamide, Azacidine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
Lymphoma, T-Cell, Peripheral
Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma
Peripheral T cell lymphomas (PTCL) are a rare hematologic disease. Five-year overall survival (OS) of PTCL patients (pts) ranges between 20 and 30%.
- Trial name
- PTCL-06 (NCT01679860)
- Testing
- Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT, Clin B (CHOP- CAMPATH) Chemo-immunotherapy
- Where
- 17 sites in Italy
- Volunteers
- 92 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Peripheral T-cell Lymphoma
Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients
Revlimid is a potent immunomodulatory analogue without the teratogenic effects, which has direct anti-tumor effects, anti-angiogenic and both anti-inflammatory and T-cell costimulatory properties.
- Trial name
- NCT01036399
- Testing
- Lenalidomide
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- University of Bologna